SpliceBio Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
40
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$135M
- Investors
-
10
SpliceBio General Information
Description
Operator of a biotechnology company intended to develop genetic medicines through protein-splicing gene therapy. The company's platform allows addressing adeno-associated viruses, both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted, and is further used to treat patients who suffer from incurable genetic diseases, enabling clients to develop and produce biotherapeutics that overcome the limitations of natural introns.
Contact Information
Website
www.splice.bioCorporate Office
- Parc Científic de Barcelona
- Baldiri Reixac, 10
- 08028 Barcelona
- Spain
Corporate Office
- Parc Científic de Barcelona
- Baldiri Reixac, 10
- 08028 Barcelona
- Spain
SpliceBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series B) | 19-May-2025 | $135M | Completed | Generating Revenue | ||
| 8. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 7. Later Stage VC (Series A) | 22-Dec-2021 | Completed | Generating Revenue | |||
| 6. Grant | 10-Dec-2020 | Completed | Pre-Clinical Trials | |||
| 5. Seed Round | 19-Nov-2020 | Completed | Pre-Clinical Trials | |||
| 4. Later Stage VC | 12-Dec-2017 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 20-Apr-2015 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 13-Dec-2014 | Completed | Pre-Clinical Trials | |||
| 1. University Spin-Out | 01-Jan-2012 | Completed | Startup |
SpliceBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 44,243 | $1.179771 | $17.68 | $17.68 | 1x | $17.68 | 8.79% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
SpliceBio Comparisons
Industry
Financing
Details
SpliceBio Competitors (92)
One of SpliceBio’s 92 competitors is Neuron23, a Venture Capital-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Neuron23 | Venture Capital-Backed | South San Francisco, CA | ||||
| Stoke Therapeutics | Formerly VC-backed | Bedford, MA | ||||
| PAQ Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Brainstorm Cell Therapeutics | Corporation | New York, NY | ||||
| Minoryx | Venture Capital-Backed | Barcelona, Spain |
SpliceBio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
SpliceBio Patents
SpliceBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026057767-A1 | Use of split intein for the treatment of abca3-associated disease | Pending | 13-Sep-2024 | ||
| WO-2026013288-A1 | Split intein for use in the treatment of cep290-associated disease | Pending | 12-Jul-2024 | ||
| AU-2025209720-A1 | Use of split intein for the treatment of myo7a-associated disease | Pending | 18-Jan-2024 | ||
| WO-2025153705-A1 | Use of split intein for the treatment of myo7a-associated disease | Pending | 18-Jan-2024 | ||
| AU-2024338787-A1 | Use of split intein for the treatment of scn1a associated disease | Pending | 04-Sep-2023 | A61K48/005 |
SpliceBio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
SpliceBio Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| EQT Life Sciences | Venture Capital | Minority | ||
| Roche Venture Fund | Corporate Venture Capital | Minority | ||
| Sanofi Ventures | Corporate Venture Capital | Minority | ||
| Gilde Healthcare | PE/Buyout | Minority | ||
| New Enterprise Associates | Venture Capital | Minority |
SpliceBio FAQs
-
When was SpliceBio founded?
SpliceBio was founded in 2012.
-
Where is SpliceBio headquartered?
SpliceBio is headquartered in Barcelona, Spain.
-
What is the size of SpliceBio?
SpliceBio has 40 total employees.
-
What industry is SpliceBio in?
SpliceBio’s primary industry is Drug Discovery.
-
Is SpliceBio a private or public company?
SpliceBio is a Private company.
-
What is SpliceBio’s current revenue?
The current revenue for SpliceBio is .
-
How much funding has SpliceBio raised over time?
SpliceBio has raised $196M.
-
Who are SpliceBio’s investors?
EQT Life Sciences, Roche Venture Fund, Sanofi Ventures, Gilde Healthcare, and New Enterprise Associates are 5 of 10 investors who have invested in SpliceBio.
-
Who are SpliceBio’s competitors?
Neuron23, Stoke Therapeutics, PAQ Therapeutics, Brainstorm Cell Therapeutics, and Minoryx are some of the 92 competitors of SpliceBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
